Botanical species · safety record

Gratiola officinalis

The EFSA Compendium of Botanicals holds 9 constituent measurements and 1 adverse-effect record for Gratiola officinalis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Gratiola officinalis L.

9Constituent measurements

1Safety records

6Cited sources

14Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 14 licensed products naming Gratiola officinalis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Aerial parts
Fresh aerial parts collected before the start of flowering
Whole plant
Whole plant(s)

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Aerial part of plants	Solvent extraction	—	GC-MS	Resolve DOI
Benzene-1,2-diol	Aerial part of plants	Solvent extraction	—	GC-MS	Resolve DOI
Benzofurans	Aerial part of plants	Solvent extraction	—	GC-MS	Resolve DOI
Cucurbitacins	Unspecified	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Gratioside	Unspecified	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Hydroxymethylfurfural	Aerial part of plants	Solvent extraction	—	GC-MS	Resolve DOI
Loliolide	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Chelidonine	Live plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR) and Electron Spin Resonance (ESR) spectroscopy	No resolvable identifier
Cucurbitacins	Unspecified	Solvent extraction	—	HPLC with standard detection methods	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Neurotoxicity	Neurologic	Unspecified	Solvent extraction	House mouse (as animal)	Acute toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Polukonova, N.V., Kurchatova, M.N., Navolokin, N.A., Bucharskaya, A.B., Durnova, N.A., Maslyakova, G.N. A new extraction method of bioflavanoids from poisonous plant (Gratiola Officinalis L.). Russian open medical journal, 2014, vol. 3, no. 3. DOI
Sturm, S., Stuppner, H. Analysis of cucurbitacins in medicinal plants by high-pressure liquid chromatography-mass spectrometry. Phytochemical analysis, 2000, vol. 11, no. 2, p. 121-127. DOI
Ali, Liaqat., Rizvi, Tania Shamim., Ahmad, Manzoor., Shaheen, Farzana. New iridoid glycoside from Gratiola officinalis. Journal of asian natural products research, 2012, vol. 14, no. 12, p. 1191-1195. DOI
Ahmad, Mansoor., Muhammad, Noor., Mehjabeen., Jahan, Noor., Ahmad, Manzoor., Habib, Salman. Pharmacological and biological evaluation of extracts from Gratiola officinalis L. (Scrophulariaceae) . Pakistan journal of pharmaceutical sciences, 2012, vol. 25, no. 3, p. 657-663.
Venkov, At., Gulubov, As. Alkaloid composition of Gratiola officinalis. Natura (plovdiv, bulgaria), 1972, vol. 5, no. 1, p. 59-62.
Rothenburger, J., Haslinger, E. New cucurbitacine glycosides from Gratiola officinalis L. Monatshefte fur chemie, 1995, vol. 126, no. 12, p. 1331-1339.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature